Ultragenyx’s Setrusumab falls short in Phase 3 osteogenesis imperfecta trials
The trials did not show a statistically significant reduction in annualized clinical fracture rates compared to placebo or bisphosphonates
The trials did not show a statistically significant reduction in annualized clinical fracture rates compared to placebo or bisphosphonates
NGD Infection Prevention was formed to scale the delivery of sequence-based transmission detection
CLE, a common form of lupus erythematosus, primarily causes diverse skin lesions
Ushio, a leader in advanced optical technologies, brings a strong track record and proprietary Photobonding technology
The approval of Nuzolvence (zoliflodacin) follows a collaborative development effort with the Global Antibiotic Research and Development Partnership
All pending litigation between Biocon Biologics, Regeneron, and Bayer will be dismissed
Roche says its new assay “resolves this challenge by delivering accurate and specific results
Biocon will acquire all of Viatris’ convertible preferred equity in Biocon Biologics for $400 million in cash and $415 million in newly issued Biocon shares
The PCR-based test, delivered via Roche’s cobas liat system, allows results to be obtained during a patient consultation in GP practices and Emergency Rooms
Under the proposed terms, Vaximm would secure a $20 million upfront payment, up to $815 million tied to clinical, regulatory, and commercial milestones
Subscribe To Our Newsletter & Stay Updated